{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:25:27Z","timestamp":1789205127098,"version":"build-2803163510"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Intramural Seed Fund from the New York Blood Center to AKD"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mBio"],"published-print":{"date-parts":[[2020,12,22]]},"abstract":"<jats:p>SARS-CoV-2 is a novel virus with many unknowns. No vaccine or specific therapy is available yet to prevent and treat this deadly virus.<\/jats:p>","DOI":"10.1128\/mbio.02451-20","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T07:58:11Z","timestamp":1607932691000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":76,"title":["Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection\n                    <i>In Vitro<\/i>"],"prefix":"10.1128","volume":"11","author":[{"given":"Francesca","family":"Curreli","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Modeling &amp; Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia M. B.","family":"Victor","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Modeling &amp; Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Modeling &amp; Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Drelich","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Tong","sequence":"additional","affiliation":[{"name":"CPS Scientific, Inc., San Jose, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Te K.","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA"},{"name":"Center of Biodefense and Emerging Disease, The University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Hillyer","sequence":"additional","affiliation":[{"name":"Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2761-0506","authenticated-orcid":false,"given":"Asim K.","family":"Debnath","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Modeling &amp; Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20200163"},{"key":"e_1_3_2_3_2","unstructured":"EU Clinical Trials Register. 2020. Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number2020-001172-15."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.138420"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0072-7"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16048-4"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Zhang G Pomplun S Loftis AR Tan X Loas A Pentelute BL. 2020. The first-in-class peptide binder to the SARS-CoV-2 spike protein. bioRxiv doi:10.1101\/2020.03.19.999318. Accessed 20 March 2020.","DOI":"10.1101\/2020.03.19.999318"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.058"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2180-5"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2179-y"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.01.012"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1039\/c8sc00284c"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24203654"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.02.038"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1039\/c9cc04022f"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1179064417713197"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/cb501020r"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2017.06.013"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00456"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02241-16"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-396962-0.00001-X"},{"key":"e_1_3_2_23_2","unstructured":"Aileron Therapeutics Inc. 2020. Clinical programs: ALRN-6924. Aileron Therapeutics Inc Watertown MA. https:\/\/www.aileronrx.com\/clinical-development\/."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0222-z"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01465"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470559277.ch110042"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099191"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm4011675"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002713107"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.6b00386"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201181"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1743767"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16505-0"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/5.3.191"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300895"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.1016"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.11.6705-6711.1995"},{"key":"e_1_3_2_38_2","volume-title":"TCID50 (50% tissue culture infectious dose) determination. Quantitation of viable HIV-1 virions in culture supernatants","author":"HIV\/AIDS Network Coordination","year":"2004","unstructured":"HIV\/AIDS Network Coordination. 2004. TCID50 (50% tissue culture infectious dose) determination. Quantitation of viable HIV-1 virions in culture supernatants. HIV\/AIDS Network Coordination, Seattle, WA. https:\/\/www.hanc.info\/labs\/labresources\/procedures\/ACTGIMPAACT%20Lab%20Manual%20Archive\/TCID50%20Determination%20-%20ARCHIVED_WM.pdf."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.007"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00433-14"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep31629"}],"container-title":["mBio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mBio.02451-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mBio.02451-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T22:06:59Z","timestamp":1646690819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mBio.02451-20"}},"subtitle":[],"editor":[{"given":"Nancy C.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12,22]]}},"alternative-id":["10.1128\/mBio.02451-20"],"URL":"https:\/\/doi.org\/10.1128\/mbio.02451-20","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.25.266437","asserted-by":"object"}]},"ISSN":["2161-2129","2150-7511"],"issn-type":[{"value":"2161-2129","type":"print"},{"value":"2150-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"assertion":[{"value":"2020-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02451-20"}}